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Abstract: We present a case of an unusual delayed multi-
systemic reaction, following treatment with pamidronate. 
Although serious adverse reactions have been reported 
with pamidronate use, such a severe reaction, late in the 
course of pamidronate treatment, has not been described 
before. An 11-month-old boy with severe and complex 
osteogenesis imperfecta (OI) presented with hyperpyrexia 
and respiratory distress 10  days after his fifth cycle of 
pamidronate. He had significant derangement of his bio-
chemical parameters including a positive urine myoglo-
bin. His respiratory distress was out of proportion to his 
chest radiograph changes. Bilevel positive airway pressure 
(BiPAP) and paediatric intensive care (PICU) admission 
were required. He was extensively investigated to exclude 
other diagnoses, but all of these investigations were nega-
tive. The reaction resembled rhabdomyolysis. He made a 
full recovery with only supportive management.
Keywords: bisphosphonates; osteogenesis imperfecta; 
rhabdomyolysis.
Background
Osteogenesis imperfecta (OI) is a group of disorders 
characterised by bone fragility in association with bone 
tissue hypermineralisation, often caused by mutations 
in genes involved in type I collagen synthesis, processing 
or transport. Bisphosphonates are drugs that reduce 
bone remodelling through the inhibition of osteoclastic 
activity, whilst allowing bone formation from modelling 
activity; so bone mass increases because newly formed 
metaphyseal trabecular bone is retained and new bone is 
added on the periosteal bone surface increasing cortical 
thickness. Bisphosphonates are widely used as first-line 
treatment of OI.
Serious adverse reactions have been reported with 
intravenous bisphosphonate use in adults including 
renal failure after several cycles, severe muscle and bone 
pain and dermatomyositis [1, 2]. Paediatric case reports 
have highlighted cases of respiratory distress following 
pamidronate infusions and also of multi-systemic disease 
in zoledronic acid use [3, 4]. We present a case of an 
unusual delayed multi-systemic reaction, following treat-
ment with pamidronate. The reaction, resembling rhab-
domyolysis and requiring paediatric intensive care (PICU) 
support, has not been reported previously to the best of 
our knowledge.
It has been found that there is a marked elevation of 
inflammatory cytokines and acute phase reactants after a 
pamidronate infusion at the dose used for osteoporosis in 
adults [5].
Case presentation
We present a case of an infant with severe and complex 
OI who had a life-threatening rhabdomyolysis-like illness 
episode 10 days after receiving a dose of pamidronate. He 
was known antenatally to have skeletal abnormalities and 
was subsequently confirmed to have a COL1A1 mutation 
confirming the diagnosis of OI. He had a stormy neonatal 
course requiring respiratory support and at 6 months of 
age developed subdural haemorrhages initially managed 
with a sub-galeal drain, but subsequently requiring a ven-
triculostomy. He had four courses of pamidronate as an 
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inpatient with gradually increasing doses, as per our local 
infant protocol [6]. There were no significant reactions 
noted with any of these.
Ten days after his fifth cycle of pamidronate, at 
11  months of age, he presented with hyperpyrexia and 
respiratory distress, requiring bilevel positive airway 
pressure (BiPAP) and admission to PICU. His respiratory 
distress was out of proportion to the chest radiograph 
changes. He had significant derangement of his biochemi-
cal parameters (see Table 1). Notably there was evidence 
of hyponatraemia, hyperkalaemia, acute kidney injury, 
abnormal liver function tests, hypocalcaemia, a raised 
ferritin and lactate dehydrogenase, thrombocytopenia 
and abnormal coagulation. His serum 25-hydroxyvitamin 
D level was normal. Supportive management with fluids 
and electrolyte replacement was commenced. After a full 
septic screen, broad spectrum antibiotics were started.
Investigations for sepsis including a blood culture, 
cerebrospinal fluid (CSF) culture, urine culture, stool 
culture and nasopharyngeal aspirate were negative. 
Blood testing for hepatitis C, adenovirus, Epstein-Barr 
virus (EBV) and cytomegalovirus polymerase chain reac-
tion (CMV PCR), HIV antibody, hepatitis B surface antigen 
and respiratory viral/Legionella PCR were also negative. 
The patient was not on any other medications prior to 
admission, making a diagnosis of malignant hyperther-
mia or other drug reactions unlikely. There was growth 
of Enterobacter cloacae in bronchoalveolar lavage. This 
was thought to be due to colonisation, not infection (low 
inflammatory markers, lack of white cells in sputum and 
previous colonisation). A liver biopsy and bone marrow 
aspirate were performed which excluded a diagnosis 
of aemophagocytic lymphohistiocytosis (HLH). Further 
investigations showed a positive urine myoglobin indicat-
ing rhabdomyolysis.
The patient gradually improved without additional 
treatment and biochemical parameters stabilised. As 
he improved clinically, it became obvious that he had 
decreased head movement, stiffness of limbs, poor inter-
action with carers and an anxious look. A computed 
tomography (CT) of the head and cervical spine was per-
formed which excluded an acute fracture or intracranial 
bleed, thus raising the possibility of myalgia and bone 
pain as a cause of his symptoms. He showed an excellent 
response to morphine, which was successfully weaned 
over several weeks. By discharge, 5 weeks after his initial 
presentation, he had returned to his normal self.
As bisphosphonates are the only current drug of 
choice that is suitable for treatment of severe OI, the deci-
sion was made to give further cycles of bisphosphonates 
at a reduced dose. A dose of 1 mg/kg of prednisolone was 
given on the day of the pamidronate infusion to reduce 
any immune response. The patient was reviewed a week 
later. He remained well and showed no changes in his bio-
chemical parameters. Further doses of pamidronate have 
been given with prednisolone cover. These doses have 
been associated with episodes of pyrexia and periods of 
feeling unwell but there were no concurrent biochemi-
cal abnormalities. These episodes required symptomatic 
management with paracetamol only.
All data were anonymised and informed consent was 
obtained from all individuals included in this study.
Discussion
The acute presentation, absence of other underlying 
causes and temporal relation to pamidronate therapy 
raised the possibility of a pamidronate-associated adverse 
reaction. Differential diagnoses initially included sepsis/
viral infection, other drug reactions, an intracranial bleed, 
fracture and HLH. All of these were excluded.
Our patient had a rise in creatinine kinase and myo-
globin in urine fitting the criteria of rhabdomyloysis [7]. 
Myoglobinuria is pathognomonic of rhabdomyolysis and 
is highly sensitive for its diagnosis. He also suffered from 
the complications of rhabdomyolysis including hyper-
kalaemia, hypocalcaemia, hyperuricaemia, raised cre-
atinine, acute kidney injury, acidosis, deranged clotting 
and volume depletion [7]. Treatment with early, aggres-
sive, supportive therapy is also associated with excellent 
outcome as seen in our case.
Table 1: Blood results of the patient at initial presentation and then 
1 week after the insult after supportive treatment only.






Sodium 154 mmol/L 139 mmol/L 135–145
Potassium 2.3 mmol/L 4.1 mmol/L 3.5–4.5
Urea 18 mmol/L 2.9 mmol/L 2.3–6.4
Creatinine 53 µmol/L 19 µmol/L 20–52
C-reactive protein <4 mg/L <4 mg/L 0–8
Creatinine kinase 30,553 IU/L 868 IU/L 24–195
Adjusted calcium 1.79 mmol/L  2.68 mmol/L 2.15–2.74
Phosphate 1.48 mmol/L  0.73 mmol/L 1.13–2.20
AST 994 IU/L 54 IU/L 15–58
ALT 310 IU/L 84 IU/L 9–36
Alkaline phosphatase 185 IU/L 530 IU/L 87–323
Lactate dehydrogenase  390 IU/L – 500–920
Ferritin 2681 ng/mL 664 ng/mL 29–371
AST, aspartate transaminase; ALT, alanine transaminase.
Park et al.: Severe reaction with bisphosphonates   3
Mild reactions to pamidronate are widely known. 
However, literature is sparse regarding acute, severe 
reactions. Trivedi et al. [3] reported a case of respiratory 
distress and multisystem involvement presenting as pro-
gressive tachycardia, fever, hypotension requiring vaso-
pressor infusion and increasing oxygen requirements 
with zoledronate. However, this young boy already had 
long-term ventilatory requirements and went on to have 
a pulmonary haemorrhage [3]. Munn et al. [4] described 
four cases of respiratory distress following pamidronate 
infusions in children with OI. This always occurred after 
the first cycle. Two infants required intensive care.
Bisphosphonates are known to have side effects 
including a rise in body temperature and flu-like symp-
toms that resemble a typical acute phase response. The 
mechanism for this response appears to be associated 
with the release of tumour necrosis factor (TNF)-alpha 
and interleukin (IL)-6 [8]. It is possible that our patient 
had an extreme activation of this pathway when using 
pamidronate and that the use of steroids alongside the 
dose has dampened down any further reactions. Low 
doses of prednisolone appear to be beneficial, but higher 
doses do not further improve outcomes when used in 
sepsis [9] and may in fact be detrimental to long-term 
bone health, which was taken into consideration when 
giving steroid cover.
Our patient seems to have had an unusual, previ-
ously unreported, reaction to pamidronate treatment after 
several previous cycles being uneventful.
What is new?
We postulate that this was a severe, adverse reaction to 
pamidronate that has not previously been reported in the 
paediatric literature. It is important to include rhabdomy-
olysis in the list of possible adverse reactions to treatment 
with pamidronate in children. A yellow card has been sub-
mitted to the Medicines and Healthcare products Regula-
tory Agency (MHRA).
Learning points
1. Bisphosphonates are the first-line therapy in OI.
2. Significant adverse reactions have previously
been reported in the form of respiratory distress,
acute systemic inflammatory reaction and renal
dysfunction.
3. The adverse reactions are usually with the first dose
of the infusion.
4. A severe, adverse reaction with multisystem involve-
ment occurred after the fourth cycle of pamidronate
which has previously not been reported.
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